Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001172661-26-001269
Filing Date
2026-02-17
Accepted
2026-02-17 21:55:22
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 8804
  Complete submission text file 0001172661-26-001269.txt   10688
Mailing Address 510 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10022
Business Address 510 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10022 (212) 231-4932
ARMISTICE CAPITAL, LLC (Filed by) CIK: 0001601086 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G

Mailing Address 1 CASPIAN POINT CASPIAN WAY CARDIFF United Kingdom CF10 4DQ
Business Address 1 CASPIAN POINT CASPIAN WAY CARDIFF United Kingdom CF10 4DQ 44 (0)1235 888300
Biodexa Pharmaceuticals Plc (Subject) CIK: 0001643918 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-89366 | Film No.: 26645144
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)